CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock, Par Value	Additional Paid in Capital	Deficit Accumulated	Non-Controlling interest	Total
Balance at Dec. 31, 2011	$ 6,000	$ 79,401,000	$ (69,609,000)		$ 9,798,000
Balance (in shares) at Dec. 31, 2011	54,279,906
Increase (Decrease) in Stockholders' Equity
Common stock issued via underwritten public offering	1,000	55,861,000			55,862,000
Common stock issued via underwritten public offering (in shares)	12,315,654
Fees and expenses related to issuing stock		(3,774,000)			(3,774,000)
Stock based compensation expense		2,297,000			2,297,000
Common stock issued for services rendered		93,000			93,000
Common stock issued for services rendered (in shares)	26,272
Net loss for the period			(39,444,000)		(39,444,000)
Balance at Dec. 31, 2012	7,000	133,878,000	(109,053,000)		24,832,000
Balance (in shares) at Dec. 31, 2012	66,621,832
Increase (Decrease) in Stockholders' Equity
Common stock issued via registered direct offering	2,000	94,732,000			94,734,000
Common stock issued via registered direct offering (in shares)	17,133,093
Fees and expenses related to issuing stock		(5,623,000)			(5,623,000)
Stock based compensation expense		4,489,000			4,489,000
Exercise of stock options		119,000			119,000
Exercise of stock options (in shares)	61,787
Cancellation of unregistered shares owned by former controlling shareholder (Callisto)	(2,000)	2,000
Cancellation of unregistered shares owned by former controlling shareholder (Callisto) (in shares)	(22,294,976)
Common stock issued to former Callisto shareholders	3,000	(3,000)
Common stock issued to former Callisto shareholders (in shares)	28,605,379
Fair value of warrants reclassified to additional paid in capital		3,575,000			3,575,000
Recapitalization of Synergy		(4,904,000)			(4,904,000)
Common stock issued for services rendered		250,000			250,000
Common stock issued for services rendered (in shares)	55,000
Net loss for the period			(62,124,000)		(62,124,000)
Balance at Dec. 31, 2013	10,000	226,515,000	(171,177,000)		55,348,000
Balance (in shares) at Dec. 31, 2013	90,182,115				90,182,115
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement	1,000	30,699,000			30,700,000
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement (in shares)	6,417,650
Fees and expenses related to issuing stock		(846,000)			(846,000)
Stock based compensation expense		4,722,000			4,722,000
Exercise of stock options		36,000			36,000
Exercise of stock options (in shares)	9,999
Private placement of ContraVir common stock		3,224,000			3,224,000
Fees and expenses associated with ContraVir Private Placement		(15,000)			(15,000)
Fair value of ContraVir warrants issued in connection with private placement		(880,000)			(880,000)
Noncontrolling interest of ContraVir				(1,622,000)	(1,622,000)
Distribution of ContraVir common stock to Synergy shareholders		(1,740,000)			(1,740,000)
Elimination of noncontrolling interest of ContraVir upon distribution				1,622,000	1,622,000
Net loss for the period			(95,708,000)		(95,708,000)
Balance at Dec. 31, 2014	$ 11,000	$ 261,715,000	$ (266,885,000)		$ (5,159,000)
Balance (in shares) at Dec. 31, 2014	96,609,764				96,609,764